Marshall Wace
RANI icon

Marshall Wace’s Rani Therapeutics RANI Stock Holding History

Marshall Wace’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Buy
+586,265
New +$520K ﹤0.01% 2568
2024
Q3 		– Sell
-21,247
Closed -$80.7K – 2881
2024
Q2 		$80.7K Buy
+21,247
New +$110K ﹤0.01% 2409

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Marshall Wace's RANI Position: Q2 2026 in Review

Marshall Wace opened a new position in Rani Therapeutics (RANI) in Q2 2026: 586,265 shares worth $446K. The stake represents ﹤0.01% of the portfolio and ranks #2568 among its holdings. This is a return to the name: Marshall Wace previously reported a position in RANI as recently as Q2 2024.

Marshall Wace first reported a position in RANI in Q2 2024 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Marshall Wace held 586,265 shares of Rani Therapeutics worth $446K as of Q2 2026.
  • Rani Therapeutics was a new Marshall Wace position in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2568 holding.
  • Marshall Wace first reported a position in Rani Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.